Table 2.
Rate of complications according to the presence of liver cirrhosis and COVID-19 infection (n = 732)
| Variable | LC+ COVID+ (n = 67) | LC+ COVID− (n = 332) | LC− COVID+ (n = 333) | p value |
|---|---|---|---|---|
| Severe complicationsa | 18 (26.9) | 54 (16.3) | 60 (18.0) | 0.12 |
| Oxygen therapya | 12 (17.9) | 32 (9.6) | 49 (14.7) | 0.06 |
| Vasopressors | 4 (6.0) | 14 (4.2) | 11 (3.3) | 0.56 |
| Admission to intensive care unit | 2 (3.0) | 9 (2.7) | 8 (2.4) | 0.95 |
| Continuous renal replacement therapy | 1 (1.5) | 1 (0.3) | 3 (0.9) | 0.45 |
| Death | 6 (9.0) | 32 (9.6) | 23 (6.9) | 0.44 |
| LC-related complications | 3 (4.5) | 30 (9.0) | - | 0.22 |
| Variceal bleeding | 2 (3.0) | 15 (4.5) | - | 0.57 |
| Ascites | 2 (3.0) | 23 (6.9) | - | 0.22 |
| Hepatorenal syndrome | 0 | 3 (0.9) | - | 0.99 |
| Spontaneous bacterial peritonitis | 0 | 1 (0.3) | - | 0.99 |
| Encephalopathy | 3 (4.5) | 17 (5.1) | - | 0.99 |
Values are presented as number (%).
COVID-19, coronavirus disease 2019; LC, liver cirrhosis.
a
p < 0.05 between LC+ COVID+ and LC+ COVID−.